<DOC>
	<DOCNO>NCT00726479</DOCNO>
	<brief_summary>The primary objective study investigate effect 4-week treatment 7.5 mg b.i.d , 15 mg q.d 15 mg b.i.d . BIBW 2948 BS placebo cough sputum determine CASA-Q ( Cough Sputum Assessment Questionnaire</brief_summary>
	<brief_title>Safety Efficacy 4-weeks Treatment BIBW 2948 BS Patients With Chronic Obstructive Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<criteria>1 . Patients must sign informed consent consistent ICHGCP guideline prior participation trial , include medication washout restriction . 2 . Male female patient 40 year age old . 3 . Patients must diagnosis COPD define postbronchodilator FEV1 &lt; 80 % predict FEV1 &lt; 70 % FVC ( obtain 30 minute administration salbutamol HFA ) . Predicted normal value calculate accord ECSC ( R941408 ) . For Height measure inch Males : FEV1 predict ( L ) = 4.30 x ( height ( inch ) /39.37 ) 0.029 x age ( yr ) 2.49 Females : FEV1 predict ( L ) = 3.95 x [ height ( inch ) /39.37 ] 0.025 x age ( yr ) 2.60 Height measure meter Males : FEV1 predict ( L ) = 4.30 x [ height ( meter ) ] 0.029 x age ( yr ) 2.49 Females : FEV1 predict ( L ) = 3.95 x [ height ( meter ) ] 0.025 x age ( yr ) 2.60 4 . Patients must diagnosis chronic bronchitis symptom i.e. , cough sputum expectoration day least three month two consecutive year . 5 . Patients must current exsmoker smoke history sup egal 10 pack year ( Patients never smoke cigarette must exclude ) . 6 . Patients must able perform specify procedure able maintain necessary record study period require protocol . 7 . Patients must able inhale medication competent manner HandiHalerÂ® device BIBW 2948 BS . 8 . Patients must able read understand questionnaire languages provide ( English U.S. , French France German Germany ) . 1 . Patients significant disease COPD exclude . A significant disease define disease condition , opinion investigator , may put patient risk participation study may influence either result study patient 's ability participate study.Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis abnormality define significant disease define exclusion criterion No . 1 . 2 . Patients acute chronic hepatitis alpha one antitrypsin deficiency liver disease . 3 . Patients aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) 1.5 x upper limit normal range exclude regardless clinical condition . A repeat laboratory evaluation conduct patient . 4 . Patients history asthma allergic rhinitis . 5 . Patients history postnasal drip last 3 month prior visit 1 . 6 . Patients clinical diagnosis bronchiectasis . 7 . Patients currently treat expectorant and/or mucolytics drug . 8 . Patients take medication know cough promote side effect ( e.g. , angiotensin convert enzyme inhibitor angiotensin II receptor blocker ) opinion investigator cause symptom cough . 9 . Patients respiratory tract infection COPD exacerbation 30 day prior visit 1 1week period prior visit 2 ( visit 2 postpone patient discontinue study ) . 10 . Patients change respiratory medication within last 6 week prior visit 1 . 11 . Patients history thoracotomy reason evaluate per Exclusion 1 . 12 . Patients history gastroesophageal reflux disease change medication ( dose intensification change therapy ) treat disease within 6 week prior visit 1 . 13 . Patients history cancer , treat basal cell carcinoma , within last five year . 14 . Women childbearing potential postmenopausal duration least 2 year hysterectomy tubal ligation procedure . 15 . Participation another trial investigational drug within 30 day 6 half life ( whichever great ) start study . 16 . A known hypersensitivity lactose component inhalation capsule component inhalation capsule delivery system . 17 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program within four week prior visit 1 . 18 . Patients significant history significant alcohol drug abuse . 19 . Patients previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>